The studies conducted indicated that all assessed proteoglycans, i.e., aggrecan, decorin, and biglycan, undergo quantitative changes in the blood plasma of patients with juvenile idiopathic arthritis throughout the course of the disease or biological treatment, as presented in Table 1. This evidence concerns the gene ACAN and juvenile idiopathic arthritis.